XML 41 R18.htm IDEA: XBRL DOCUMENT
v3.25.2

Segments of Business and Geographic Areas | 6 Months Ended
--- | ---
Jun. 29, 2025
Segment Reporting [Abstract] |
Segments of Business and Geographic Areas | Segments of business and geographic areas The Company is organized into two business segments: Innovative Medicine and MedTech. The Company’s chief operating decision maker (CODM) is the Chief Executive Officer (Principal Executive Officer). For the Innovative Medicine and MedTech segments, the CODM uses segment income before tax to allocate resources (including employees, financial, and capital resources) for each segment predominantly in the annual forecasting process. The CODM considers planning-to-actual variances on a quarterly basis to assess performance and make decisions about allocating resources to the segments. Sales by segment of business
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $3,385 |  | 2,636 |  | 28.4 | % |  | $6,398 |  | 5,019 |  | 27.5 | %
International |  | 2,928 |  | 2,455 |  | 19.3 |  |  | 5,592 |  | 4,885 |  | 14.5 |
Worldwide |  | 6,312 |  | 5,090 |  | 24.0 |  |  | 11,990 |  | 9,904 |  | 21.1 |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 358 |  | 167 |  | * |  | 676 |  | 307 |  | *
International |  | 81 |  | 20 |  | * |  | 132 |  | 36 |  | *
Worldwide |  | 439 |  | 186 |  | * |  | 808 |  | 343 |  | *
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,017 |  | 1,641 |  | 23.0 |  |  | 3,846 |  | 3,105 |  | 23.9 |
International |  | 1,521 |  | 1,237 |  | 23.0 |  |  | 2,930 |  | 2,465 |  | 18.9 |
Worldwide |  | 3,539 |  | 2,878 |  | 23.0 |  |  | 6,776 |  | 5,570 |  | 21.7 |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 378 |  | 318 |  | 18.6 |  |  | 670 |  | 603 |  | 11.0 |
International |  | 530 |  | 418 |  | 27.0 |  |  | 1,009 |  | 822 |  | 22.9 |
Worldwide |  | 908 |  | 736 |  | 23.4 |  |  | 1,679 |  | 1,425 |  | 17.8 |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 239 |  | 246 |  | (2.7) |  |  | 474 |  | 511 |  | (7.3) |
International |  | 496 |  | 525 |  | (5.4) |  |  | 970 |  | 1,043 |  | (6.9) |
Worldwide |  | 735 |  | 770 |  | (4.5) |  |  | 1,444 |  | 1,554 |  | (7.0) |
RYBREVANT/ LAZCLUZE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 139 |  | 52 |  | * |  | 252 |  | 88 |  | *
International |  | 41 |  | 17 |  | * |  | 69 |  | 28 |  | *
Worldwide |  | 179 |  | 69 |  | * |  | 320 |  | 116 |  | *
TALVEY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 82 |  | 59 |  | 38.0 |  |  | 150 |  | 109 |  | 36.7 |
International |  | 24 |  | 9 |  | * |  | 42 |  | 17 |  | *
Worldwide |  | 106 |  | 69 |  | 55.0 |  |  | 192 |  | 127 |  | 52.0 |
TECVAYLI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 114 |  | 104 |  | 8.2 |  |  | 219 |  | 205 |  | 6.6 |
International |  | 52 |  | 30 |  | 74.8 |  |  | 98 |  | 63 |  | 56.0 |
Worldwide |  | 166 |  | 135 |  | 23.1 |  |  | 317 |  | 268 |  | 18.2 |
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6 |  | 11 |  | (38.9) |  |  | 13 |  | 20 |  | (31.9) |
International |  | 139 |  | 154 |  | (9.8) |  |  | 257 |  | 326 |  | (21.1) |
Worldwide |  | 145 |  | 165 |  | (11.6) |  |  | 270 |  | 346 |  | (21.7) |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 50 |  | 37 |  | 36.9 |  |  | 97 |  | 70 |  | 39.8 |
International |  | 42 |  | 45 |  | (8.7) |  |  | 84 |  | 86 |  | (2.5) |
Worldwide |  | 93 |  | 83 |  | 11.7 |  |  | 182 |  | 156 |  | 16.4 |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,505 |  | 2,978 |  | (15.9) |  |  | 4,701 |  | 5,431 |  | (13.4) |
International |  | 1,489 |  | 1,744 |  | (14.6) |  |  | 2,999 |  | 3,538 |  | (15.2) |
Worldwide |  | 3,993 |  | 4,722 |  | (15.4) |  |  | 7,700 |  | 8,969 |  | (14.1) |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 283 |  | 231 |  | 22.5 |  |  | 597 |  | 497 |  | 20.1 |
U.S. Exports |  | 34 |  | 35 |  | (2.6) |  |  | 44 |  | 62 |  | (28.7) |
International |  | 138 |  | 127 |  | 8.6 |  |  | 281 |  | 268 |  | 4.8 |
Worldwide |  | 455 |  | 393 |  | 15.9 |  |  | 922 |  | 827 |  | 11.5 |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 305 |  | 267 |  | 14.0 |  |  | 597 |  | 521 |  | 14.4 |
International |  | 387 |  | 270 |  | 43.1 |  |  | 753 |  | 569 |  | 32.2 |
Worldwide |  | 690 |  | 537 |  | 28.6 |  |  | 1,349 |  | 1,091 |  | 23.7 |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,078 |  | 1,855 |  | (41.9) |  |  | 2,059 |  | 3,251 |  | (36.7) |
International |  | 575 |  | 1,030 |  | (44.2) |  |  | 1,219 |  | 2,085 |  | (41.5) |
Worldwide |  | 1,653 |  | 2,885 |  | (42.7) |  |  | 3,278 |  | 5,336 |  | (38.6) |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 796 |  | 589 |  | 35.2 |  |  | 1,395 |  | 1,098 |  | 27.1 |
International |  | 391 |  | 317 |  | 23.2 |  |  | 747 |  | 616 |  | 21.2 |
Worldwide |  | 1,186 |  | 906 |  | 31.0 |  |  | 2,142 |  | 1,714 |  | 25.0 |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8 |  | 2 |  | * |  | 9 |  | 2 |  | *
International |  | 0 |  | 0 |  | — |  | 0 |  | 0 |  | —
Worldwide |  | 8 |  | 2 |  | * |  | 9 |  | 2 |  | *
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,377 |  | 1,102 |  | 24.9 |  |  | 2,345 |  | 2,156 |  | 8.7 |
International |  | 674 |  | 679 |  | (0.8) |  |  | 1,353 |  | 1,428 |  | (5.2) |
Worldwide |  | 2,051 |  | 1,782 |  | 15.1 |  |  | 3,698 |  | 3,585 |  | 3.2 |
CAPLYTA(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 211 |  | — |  | * |  | 211 |  | — |  | *
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 211 |  | — |  | * |  | 211 |  | — |  | *
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 24 |  | 34 |  | (27.7) |  |  | 62 |  | 75 |  | (16.6) |
International |  | 139 |  | 129 |  | 7.5 |  |  | 249 |  | 265 |  | (6.0) |
Worldwide |  | 164 |  | 163 |  | 0.2 |  |  | 312 |  | 340 |  | (8.3) |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 732 |  | 784 |  | (6.7) |  |  | 1,357 |  | 1,549 |  | (12.4) |
International |  | 260 |  | 269 |  | (3.5) |  |  | 537 |  | 561 |  | (4.2) |
Worldwide |  | 992 |  | 1,054 |  | (5.9) |  |  | 1,895 |  | 2,110 |  | (10.2) |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 366 |  | 226 |  | 61.1 |  |  | 642 |  | 417 |  | 53.7 |
International |  | 50 |  | 44 |  | 12.8 |  |  | 93 |  | 78 |  | 18.1 |
Worldwide |  | 414 |  | 271 |  | 53.3 |  |  | 734 |  | 496 |  | 48.1 |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 45 |  | 57 |  | (23.5) |  |  | 73 |  | 115 |  | (37.0) |
International |  | 226 |  | 237 |  | (4.7) |  |  | 474 |  | 524 |  | (9.5) |
Worldwide |  | 270 |  | 294 |  | (8.4) |  |  | 547 |  | 639 |  | (14.4) |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 799 |  | 743 |  | 7.6 |  |  | 1,543 |  | 1,509 |  | 2.3 |
International |  | 314 |  | 296 |  | 5.8 |  |  | 595 |  | 579 |  | 2.6 |
Worldwide |  | 1,113 |  | 1,039 |  | 7.1 |  |  | 2,138 |  | 2,088 |  | 2.4 |
OPSUMIT/OPSYNVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 403 |  | 376 |  | 6.9 |  |  | 766 |  | 732 |  | 4.6 |
International |  | 180 |  | 171 |  | 5.4 |  |  | 339 |  | 340 |  | (0.3) |
Worldwide |  | 582 |  | 548 |  | 6.4 |  |  | 1,104 |  | 1,072 |  | 3.0 |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 382 |  | 349 |  | 9.4 |  |  | 747 |  | 741 |  | 0.8 |
International |  | 94 |  | 76 |  | 22.4 |  |  | 180 |  | 152 |  | 17.9 |
Worldwide |  | 476 |  | 426 |  | 11.7 |  |  | 927 |  | 894 |  | 3.7 |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 16 |  | 17 |  | (12.4) |  |  | 31 |  | 35 |  | (12.6) |
International |  | 40 |  | 49 |  | (18.5) |  |  | 77 |  | 88 |  | (12.4) |
Worldwide |  | 55 |  | 67 |  | (16.9) |  |  | 107 |  | 123 |  | (12.5) |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 320 |  | 334 |  | (4.3) |  |  | 635 |  | 658 |  | (3.6) |
International |  | 484 |  | 631 |  | (23.4) |  |  | 971 |  | 1,128 |  | (13.9) |
Worldwide |  | 803 |  | 965 |  | (16.8) |  |  | 1,605 |  | 1,786 |  | (10.1) |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 6 |  | 8 |  | (25.4) |  |  | 14 |  | 16 |  | (13.6) |
International |  | 354 |  | 288 |  | 23.0 |  |  | 704 |  | 603 |  | 16.7 |
Worldwide |  | 360 |  | 297 |  | 21.6 |  |  | 718 |  | 620 |  | 15.9 |
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 312 |  | 321 |  | (3.0) |  |  | 617 |  | 635 |  | (2.9) |
International |  | 85 |  | 117 |  | (27.0) |  |  | 183 |  | 221 |  | (17.2) |
Worldwide |  | 396 |  | 438 |  | (9.4) |  |  | 799 |  | 856 |  | (6.6) |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2 |  | 5 |  | (51.8) |  |  | 4 |  | 7 |  | (37.4) |
International |  | 45 |  | 227 |  | (80.5) |  |  | 84 |  | 304 |  | (72.5) |
Worldwide |  | 47 |  | 233 |  | (79.8) |  |  | 88 |  | 311 |  | (71.7) |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 776 |  | 717 |  | 8.2 |  |  | 1,631 |  | 1,348 |  | 21.0 |
International |  | 154 |  | 176 |  | (12.3) |  |  | 312 |  | 373 |  | (16.2) |
Worldwide |  | 930 |  | 892 |  | 4.2 |  |  | 1,943 |  | 1,721 |  | 12.9 |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 621 |  | 587 |  | 5.6 |  |  | 1,311 |  | 1,105 |  | 18.6 |
International |  | — |  | — |  | — |  |  | — |  | — |  | — |
Worldwide |  | 621 |  | 587 |  | 5.6 |  |  | 1,311 |  | 1,105 |  | 18.6 |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 155 |  | 129 |  | 20.0 |  |  | 320 |  | 243 |  | 31.6 |
International |  | 154 |  | 176 |  | (12.3) |  |  | 312 |  | 373 |  | (16.2) |
Worldwide |  | 309 |  | 305 |  | 1.4 |  |  | 632 |  | 616 |  | 2.7 |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9,161 |  | 8,510 |  | 7.6 |  |  | 17,253 |  | 16,122 |  | 7.0 |
International |  | 6,041 |  | 5,980 |  | 1.0 |  |  | 11,822 |  | 11,930 |  | (0.9) |
Worldwide |  | 15,202 |  | 14,490 |  | 4.9 |  |  | 29,075 |  | 28,052 |  | 3.6 |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,364 |  | 1,119 |  | 21.9 |  |  | 2,625 |  | 2,144 |  | 22.4 |
International |  | 948 |  | 753 |  | 25.9 |  |  | 1,790 |  | 1,534 |  | 16.7 |
Worldwide |  | 2,313 |  | 1,873 |  | 23.5 |  |  | 4,416 |  | 3,679 |  | 20.0 |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 741 |  | 705 |  | 5.1 |  |  | 1,425 |  | 1,397 |  | 2.0 |
International |  | 728 |  | 618 |  | 17.8 |  |  | 1,366 |  | 1,270 |  | 7.6 |
Worldwide |  | 1,468 |  | 1,323 |  | 11.0 |  |  | 2,791 |  | 2,667 |  | 4.7 |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 360 |  | 309 |  | 16.6 |  |  | 699 |  | 612 |  | 14.2 |
International |  | 89 |  | 72 |  | 25.0 |  |  | 170 |  | 139 |  | 22.4 |
Worldwide |  | 448 |  | 379 |  | 18.2 |  |  | 868 |  | 750 |  | 15.7 |
SHOCKWAVE(3) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 233 |  | 77 |  | * |  | 439 |  | 77 |  | *
International |  | 58 |  | 0 |  | * |  | 110 |  | 0 |  | *
Worldwide |  | 292 |  | 77 |  | * |  | 550 |  | 77 |  | *
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
OTHER CARDIOVASCULAR |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 31 |  | 29 |  | 5.4 |  |  | 63 |  | 59 |  | 6.3 |
International |  | 72 |  | 64 |  | 13.4 |  |  | 144 |  | 126 |  | 14.2 |
Worldwide |  | 104 |  | 93 |  | 10.8 |  |  | 207 |  | 185 |  | 11.7 |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,420 |  | 1,422 |  | (0.2) |  |  | 2,804 |  | 2,870 |  | (2.3) |
International |  | 885 |  | 890 |  | (0.5) |  |  | 1,742 |  | 1,782 |  | (2.2) |
Worldwide |  | 2,305 |  | 2,312 |  | (0.3) |  |  | 4,546 |  | 4,652 |  | (2.3) |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 271 |  | 265 |  | 2.1 |  |  | 534 |  | 535 |  | (0.2) |
International |  | 150 |  | 152 |  | (1.0) |  |  | 296 |  | 304 |  | (2.5) |
Worldwide |  | 421 |  | 417 |  | 1.0 |  |  | 830 |  | 839 |  | (1.1) |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 226 |  | 230 |  | (1.9) |  |  | 457 |  | 472 |  | (3.1) |
International |  | 164 |  | 163 |  | 0.0 |  |  | 322 |  | 323 |  | (0.5) |
Worldwide |  | 389 |  | 394 |  | (1.1) |  |  | 778 |  | 795 |  | (2.0) |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 501 |  | 498 |  | 0.7 |  |  | 1,003 |  | 1,002 |  | 0.1 |
International |  | 267 |  | 260 |  | 2.2 |  |  | 537 |  | 521 |  | 2.9 |
Worldwide |  | 768 |  | 759 |  | 1.2 |  |  | 1,540 |  | 1,524 |  | 1.1 |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 422 |  | 430 |  | (1.7) |  |  | 810 |  | 862 |  | (6.0) |
International |  | 305 |  | 314 |  | (2.7) |  |  | 588 |  | 634 |  | (7.2) |
Worldwide |  | 727 |  | 743 |  | (2.1) |  |  | 1,398 |  | 1,495 |  | (6.5) |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,043 |  | 995 |  | 4.8 |  |  | 2,045 |  | 1,982 |  | 3.2 |
International |  | 1,512 |  | 1,493 |  | 1.3 |  |  | 2,906 |  | 2,922 |  | (0.5) |
Worldwide |  | 2,555 |  | 2,488 |  | 2.7 |  |  | 4,951 |  | 4,904 |  | 1.0 |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 477 |  | 466 |  | 2.2 |  |  | 934 |  | 912 |  | 2.4 |
International |  | 687 |  | 675 |  | 1.9 |  |  | 1,303 |  | 1,316 |  | (1.0) |
Worldwide |  | 1,164 |  | 1,141 |  | 2.0 |  |  | 2,237 |  | 2,228 |  | 0.4 |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 567 |  | 528 |  | 7.2 |  |  | 1,111 |  | 1,070 |  | 3.8 |
International |  | 825 |  | 818 |  | 0.9 |  |  | 1,603 |  | 1,606 |  | (0.1) |
Worldwide |  | 1,391 |  | 1,346 |  | 3.3 |  |  | 2,714 |  | 2,676 |  | 1.4
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 557 |  | 523 |  | 6.5 |  |  | 1,123 |  | 1,070 |  | 4.9 |
International |  | 813 |  | 763 |  | 6.5 |  |  | 1,526 |  | 1,473 |  | 3.6 |
Worldwide |  | 1,369 |  | 1,285 |  | 6.5 |  |  | 2,648 |  | 2,543 |  | 4.1 |
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 429 |  | 409 |  | 4.8 |  |  | 881 |  | 847 |  | 3.9 |
International |  | 536 |  | 509 |  | 5.4 |  |  | 1,003 |  | 981 |  | 2.3 |
Worldwide |  | 965 |  | 918 |  | 5.1 |  |  | 1,884 |  | 1,828 |  | 3.1 |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 128 |  | 113 |  | 12.6 |  |  | 242 |  | 223 |  | 8.5 |
International |  | 277 |  | 254 |  | 8.8 |  |  | 523 |  | 492 |  | 6.2 |
Worldwide |  | 403 |  | 367 |  | 9.9 |  |  | 764 |  | 715 |  | 6.9 |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,383 |  | 4,059 |  | 8.0 |  |  | 8,596 |  | 8,067 |  | 6.6 |
International |  | 4,158 |  | 3,898 |  | 6.7 |  |  | 7,965 |  | 7,711 |  | 3.3 |
Worldwide |  | 8,541 |  | 7,957 |  | 7.3 |  |  | 16,561 |  | 15,778 |  | 5.0 |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 13,544 |  | 12,569 |  | 7.8 |  |  | 25,849 |  | 24,189 |  | 6.9 |
International |  | 10,199 |  | 9,878 |  | 3.2 |  |  | 19,787 |  | 19,641 |  | 0.7 |
Worldwide |  | $23,743 |  | 22,447 |  | 5.8 | % |  | $45,636 |  | 43,830 |  | 4.1 | %
* Percentage greater than 100% or not meaningful (1) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE (2) Acquired with the Intra-Cellular Therapies acquisition on April 2, 2025 (3) Acquired on May 31, 2024 Segment income before tax
|  | Fiscal Second Quarter Ended |  |
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  |  |  |  |  |  |  |  |  |  |
|  | Innovative Medicine(1) | MedTech(2) | Total |  | Innovative Medicine(1) | MedTech(2) | Total |  |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $15,202 | 8,541 |  |  | 14,490 | 7,957 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 3,978 | 3,638 |  |  | 3,603 | 3,248 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 2,789 | 2,862 |  |  | 2,665 | 2,671 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 2,869 | 647 |  |  | 2,722 | 718 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | 14 | 190 |  |  | 41 | 231 |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $5,552 | 1,204 | 6,756 |  | 5,459 | 1,089 | 6,548 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | 265 |  |  |  | 800 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $6,491 |  |  |  | $5,748 |  |  |  |  |  |  |  |  |  |  |
|  | Fiscal Six Months Ended |  |  |  |  |  |  |  |  |  |
Sales to customers |  | $29,075 | 16,561 |  |  | 28,052 | 15,778 |  |  |  |  |  |  |  |  |  |  |  |
Cost of products sold |  | 7,998 | 6,964 |  |  | 6,973 | 6,368 |  |  |  |  |  |  |  |  |  |  |  |
Selling, marketing and administrative |  | 5,050 | 5,518 |  |  | 5,103 | 5,253 |  |  |  |  |  |  |  |  |  |  |  |
Research and development expense |  | 5,417 | 1,324 |  |  | 5,618 | 1,364 |  |  |  |  |  |  |  |  |  |  |  |
Other segment items (3) |  | (152) | 130 |  |  | (70) | 184 |  |  |  |  |  |  |  |  |  |  |  |
Segment income before tax |  | $10,762 | 2,625 | 13,387 |  | 10,428 | 2,609 | 13,037 |  |  |  |  |  |  |  |  |  |  |
(Income)/Expense not allocated to segments (4) |  |  |  | (6,735) |  |  |  | 3,575 |  |  |  |  |  |  |  |  |  |  |
Earnings before provision for taxes on income |  |  |  | $20,122 |  |  |  | $9,462 |  |  |  |  |  |  |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.8 billion and $0.7 billion in the fiscal second quarter of 2025 and 2024, respectively. Intangible amortization expense of $1.4 billion in both the fiscal six months of 2025 and 2024. •Acquisition and integration related expense of $0.2 billion in both the fiscal second quarter of 2025 and fiscal six months of 2025, primarily related to the Intra-Cellular acquisition. •An In-process research and development impairment of $0.2 billion in the fiscal second quarter and fiscal six months of 2024 associated with the M710 (biosimilar) asset acquired from Momenta in 2020. •Restructuring income of $0.1 billion in the fiscal second quarter of 2024 and a restructuring related charge of $0.1 billion in the fiscal six months of 2024. (2) MedTech includes: •Intangible amortization expense of $0.5 billion and $0.4 billion in the fiscal second quarter of 2025 and 2024, respectively. Intangible amortization expense of $1.0 billion and $0.8 billion in the fiscal six months of 2025 and 2024, respectively. •Acquisition, integration and divestiture related net expense of $0.1 billion in the fiscal six months of 2025. Acquisition and integration related expense of $0.4 billion and $0.5 billion, in the fiscal second quarter and fiscal six months of 2024, respectively, primarily driven by the Abiomed and Shockwave acquisitions. •A restructuring related charge of $0.1 billion in both the fiscal second quarter and fiscal six months of 2025 and 2024. Refer to Note 12 for additional details. (3) Other segment expenses for each reportable segment include charges related to other income and expense, restructuring activities and impairment charges related to in-process research and development. (4) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal six months of 2025 includes the reversal of approximately $7.0 billion, a significant portion of the previously accrued talc reserve. The fiscal second quarter and fiscal six months of 2024 includes charges for talc matters of $0.3 billion and $3.0 billion, respectively. For additional details related to talc refer to Note 11 to the Consolidated Financial Statements. The fiscal second quarter and six months of 2024 includes a loss of approximately $0.4 billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock.
|  | Identifiable Assets
(Dollars in Millions) |  | June 29, 2025 |  | December 29, 2024
Innovative Medicine |  | $75,487 |  | 57,070
MedTech |  | 86,745 |  | 84,322
Total |  | 162,232 |  | 141,392
General corporate (1) |  | 31,157 |  | 38,712
Worldwide total |  | $193,389 |  | 180,104
(1)General corporate includes cash, cash equivalents, marketable securities and other corporate assets.
|  | Additions to Property, Plant & Equipment |  | Depreciation and Amortization
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | June 29, 2025 |  | June 30, 2024
Innovative Medicine |  | $687 |  | 553 |  | $1,925 |  | 1,861
MedTech |  | 1,071 |  | 1,074 |  | 1,678 |  | 1,552
Segments total |  | 1,758 |  | 1,627 |  | 3,603 |  | 3,413
General corporate |  | 80 |  | 156 |  | 112 |  | 184
Worldwide total |  | $1,838 |  | 1,783 |  | $3,715 |  | 3,597
Sales by geographic area
|  | Fiscal Second Quarter Ended |  | Fiscal Six Months Ended
(Dollars in Millions) |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change |  | June 29, 2025 |  | June 30, 2024 |  | Percent Change
United States |  | $13,544 |  | 12,569 |  | 7.8 | % |  | $25,849 |  | 24,189 |  | 6.9 | %
Europe |  | 5,387 |  | 5,214 |  | 3.3 |  |  | 10,497 |  | 10,377 |  | 1.1 |
Western Hemisphere, excluding U.S. |  | 1,206 |  | 1,212 |  | (0.5) |  |  | 2,373 |  | 2,406 |  | (1.3) |
Asia-Pacific, Africa |  | 3,606 |  | 3,452 |  | 4.4 |  |  | 6,917 |  | 6,858 |  | 0.9 |
Total |  | $23,743 |  | 22,447 |  | 5.8 | % |  | $45,636 |  | 43,830 |  | 4.1 | %

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration